Overview

A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
A Phase 2, 2 part trial to evaluate the safety and efficacy of galeterone in castration resistant prostate cancer (CRPC) patients.
Phase:
Phase 2
Details
Lead Sponsor:
Novus Therapeutics, Inc
Tokai Pharmaceuticals
Treatments:
3-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene